Form 4: Ionis Pharmaceuticals Executive VP Joseph Baroldi Reports Stock Transactions

Executive VP Joseph Baroldi of Ionis Pharmaceuticals reports the acquisition and disposal of company stock and restricted stock units.

Summary

• Joseph Baroldi, Executive VP and Chief Business Officer of Ionis Pharmaceuticals, reported transactions involving the company's common stock and restricted stock units.
• On April 15, 2025, Baroldi acquired 10,837 shares of common stock through the vesting of restricted stock units.
• On April 16, 2025, he sold 3,928 shares of common stock at a weighted average price of $28.4 per share to cover tax withholding obligations.
• Following these transactions, Baroldi directly owns 31,926 shares of common stock and indirectly owns 3,071 shares through a spouse.
• He also holds 66,511 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions, which carries a neutral sentiment.

Industry Context

This is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely insignificant given the volume of shares traded.

Key Dates

Keywords

Ionis Pharmaceuticals, Joseph Baroldi, stock transaction, restricted stock units, Form 4, IONS